Diasorin S.p.a. · MIL:DIA

Diasorin — Q1 2018 Earnings Presentation

18 slides from Diasorin's earnings presentation, May 8, 2018

  1. Slide 1: Q1 2018 Results

    Q1 2018 Results DIASORIN SPA May 8, 2018

  2. Slide 2: Disclaimer

    Disclaimer These statements are related, among others, to the intent, belief or current expectations of the customer base, estimates regarding future growth in the different business lines and the global business, market share, financial results and other aspects of the activities and situation rela

  3. Slide 3: Agenda

    4 Highlights Q1 Main Topics Revenues • Breakdown by Technology • Breakdown by Geography Installed Base Expansion Profitability Profile 12 FY 2018 Company Guidance 14 Annex 3

  4. Slide 4: Highlights

    Highlights

  5. Slide 5: Q1'18 main topics

    Q1’18 main topics Q1’18 Q1’18 @ March 31, 2018 LIAISON & LIAISON XL PLACEMENTS €/mln 164.5 (*) REVENUES LIAISON XL +116 3,634 +4.4% +11.2% (**) CLIA ex Vit D 25 OH +9.1% +13.8% (**) LIAISON -13 3,867 Vit D 25 OH -11.5% -2.6% (**) TOTAL +103 7,501 ELISA tests +18.2% +24.4% (**) Molecular tests +4.8%

  6. Slide 6: Q1'18 Revenues

    Q1’18 Revenues Q1’18 vs. Q1’17 Growth driven by • all CLIA tests, net of Vitamin D 25 OH, with particular evidence on: @ current +4.4% • Infectious Diseases • Hepatitis • Torch Revenues • Gastro-Intestinal Testing • Vitamin D 1,25 • molecular tests, with a strong flu season • positive contribution c

  7. Slide 7: Revenues: breakdown by technology

    Q1’18 Revenues: breakdown by technology Q1’18 vs. Q1’17 @ current +9.1% CLIA ex Vitamin D 25 OH tests @ CER +13.8% CLIA @ current -11.5% Vitamin D 25 OH test (CLIA) @ CER -2.6% @ current +18.2% ELISA tests (*) @ CER +24.4% @ current +4.8% Molecular Diagnostic tests @ CER +19.1% @ current -1.6% Instr

  8. Slide 8: Revenues: breakdown by geography

    Q1’18 Revenues*: breakdown by geography Q1’18 Q1’18 vs. vs. Q1’17 Q1’17 EUROPE & AFRICA +16.4% ASIA PACIFIC +15.8% Germany +23.5% China +0.9% Growth mainly driven by Gastro-Intestinal testing, Vitamin D 1,25 and Siemens’ Growth in CLIA tests (+17.8%) driven by Hepatitis, Prenatal diseases and thyroi

  9. Slide 9: Revenues Breakdown

    Q1’18 Revenues Breakdown BY GEOGRAPHY BY TECHNOLOGY Instruments, consumables & others: Q1’17 Q1’17 11.2% North America: Molecular tests: 33.7% 11.6% Europe and Africa: 42.4% ELISA tests: 11.8% CLIA tests: 65.4% Asia Pacific: 16.6% Central and South America: 7.3% Q1’18 (*) Q1’18 (*) Instruments, cons

  10. Slide 10: Installed base expansion

    Installed base expansion 7,305 7,398 7,501 7,035 7,197 6,862 LAS 2,863 +185 3,048 +185 3,233 +149 3,382 +136 3,518 +116 3,634 -12 -23 -41 -43 -13 3,999 3,987 3,964 3,923 3,880 3,867 2016 Q1'17 H1'17 9M'17 2017 Q1'18 Q1 2018 Results Presentation 10

  11. Slide 11: EBITDA

    Q1’18 EBITDA* Q1’17 Q1’18 Change % Q1’18 @ CER Change % @ CER EBITDA (€/mln) 62.5 63.3 +1.3% 68.3 +9.3% EBITDA 39.7% 38.5% -120 bps 39.0% -70 bps margin Variance versus Q1’17 mainly driven by: • higher sales as a consequence of:  growth of immunodiagnostic products, mainly driven by CLIA ex Vitamin

  12. Slide 12: FY 2018 Company Guidance

    FY 2018 Company Guidance

  13. Slide 13: FY 2018 Company Guidance

    FY 2018 Company Guidance Revenues Growth equal to around +11% at CER compared with 2017 (*) EBITDA Growth equal to around +13% at CER compared with 2017 (*) (*) 2017 €/US$ avg. exchange rate = 1.13 Q1 2018 Results Presentation 13

  14. Slide 14: Annex

    Annex

  15. Slide 15: Q1'18 results: Income Statement

    Q1’18 results: Income Statement Q1 Change Data in € million 2017 2018 amount % Net revenues 157.5 164.5 +7.0 +4.4% Gross profit 107.9 111.2 +3.3 +3.0% Gross Margin 68.5% 67.6% -93 bps S&M (29.8) (31.7) -1.9 +6.3% R&D (10.2) (11.7) -1.5 +14.7% G&A (16.0) (15.1) +0.9 -5.7% Total operating expenses (56

  16. Slide 16: Q1'18 results: Balance Sheet

    Q1’18 results: Balance Sheet Data in € million 12/31/2017 3/31/2018 Change Goodwill and intangibles assets 347.1 344.6 -2.5 Property, plant and equipment 92.4 90.8 -1.6 Other non-current assets 23.8 24.5 +0.7 Net working capital 191.9 206.8 +14.9 Other non-current liabilities (62.5) (63.7) -1.2 Net

  17. Slide 17: Q1'18 results: Cash Flow Statement

    Q1’18 results: Cash Flow Statement Q1 Data in € million Change 2017 2018 Cash and cash equivalents at the beginning of the period 130.5 159.3 +28.9 Operating activities 51.2 37.6 -13.6 Investing activities (8.0) (10.0) -2.1 Financing activities (0.8) (3.5) -2.7 Acquisitions of companies and business

  18. Slide 18: Slide 18

DiaSorin — Q1 2018 Earnings Presentation on 6ix